TNFRSF4 and sarcoma: It is interesting to note that even though mouse sarcomas treated with combination therapy closely resembled human SIC D and E tumors, in our experimental system, they did not respond to anti-PD1 treatment alone or in any combination with RT, CpG, and/or OX-40 agonist antibody (Supplemental Figure 6A).